ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.

Condition:   Breast CancerIntervention:   Drug: EribulinSponsor:   Imperial College LondonRecruiting - verified January 2016
Source: - Category: Research Source Type: clinical trials

Related Links:

Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
The EO771 cell line presents a molecular pattern ER α‐, ERβ +, PR+ and ErbB2+ and could be considered as a luminal B subtype. The EO771 tumour‐bearing mouse model presents the great interest of developing an immunocompetent mammary neoplastic model using an orthotopic injection. AbstractAmong mouse mammary tumor models, syngeneic cell lines present an advantage for the study of immune response. However, few of these models are well characterized. The tumor line EO771 is derived from spontaneous breast cancer of C57BL/6 mice. These cells are widely used but are referenced under different names: EO771, EO 771,...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
A team of Irish scientists may have discovered a potential new treatment option for patients with breast cancer who are resistant to hormone therapy, according to a study published in the journalCancer
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
Introduction: Current guidelines recommend the use of hormone therapy plus CDK 4/6 inhibitors (CDK4/6i) as initial treatments in patients (pts) with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). The subgroup analyses of phase III studies of CDK4/6i did not identify any predictive marker that could help the clinicians to address the therapeutic choice.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Advanced Disease Source Type: research
We report the case of a 52-year-old woman who underwent the removal of a parietal skin lesion. The histological and immunohistochemical analyses suggested a breast cancer origin. Clinical assessme nt and laboratory and radiological examinations did not locate the primary tumor. Hormone therapy was offered to the patient; however, she refused it. After 28 months, the patient reported a right cervical lump, and a total-body positron emission tomography showed dissemination of the disease to the lymph nodes and bone. A CUP syndrome from OBC was diagnosed. A multimodality approach with radiotherapy and hormone and biological t...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Piña-Sánchez P, Valdez-Salazar HA, Ruiz-Tachiquín ME Abstract Breast cancer (BC) is the most common type of cancer in women worldwide, and despite advances in treatments, its incidence and mortality are increasing. Therefore, it is necessary to develop new, non-invasive tests that provide more accurate diagnosis and prognosis in a timely manner. A promising approach is measuring the presence of biomarkers to detect tumors at various stages and determine their specific characteristics, thus allowing for more personalized treatment. MicroRNAs (miRNAs) serve a role in gene expression, pri...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
uet D Abstract Breast cancer is the most frequently diagnosed cancer in women and the first cause of cancer death in France. Among the different subtypes of breast cancer, the predominant form is characterized by positive hormone receptors (more than 70% of breast cancers). Hormone therapy thus plays a key role in the strategy of management of these cancers both in adjuvant and metastatic situations. The two types of adjuvant hormone therapy used are selective estrogen receptor modulators and aromatase inhibitors. Fulvestrant, an anti-estrogen, is used alone or in combination with other molecules in metastatic sit...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
Combining  abemaciclib with hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, interim analysis of a phase III study has suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conditions:   Web-application;   Breast Cancer;   Hormono Therapy Interventions:   Other: WEB-Application;   Other: Standard accompaniment Sponsor:   Centre Francois Baclesse Recruiting
Source: - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Research | Study